LLY
Eli Lilly and Company
LLY has the edge over XGN overall, supported by stronger fundamentals and lower modeled downside.
XGN
Exagen Inc.
XGN's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
XGN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
XGN's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
XGN PE Valuation
XGN has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
XGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect XGN's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over XGN on earnings quality, reporting a profit while its opponent remains loss making.
XGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.76 | +$0.16 |
| Q2 2026 | -$0.82 | +$0.07 |
| Q1 2026 | -$0.90 | -$0.06 |
| Q4 2025 | -$0.93 | -$0.10 |
| Q3 2025 | -$0.92 | +$0.02 |
| Q2 2025 | -$0.89 | +$0.08 |
| Q1 2025 | -$0.84 | +$0.25 |
| Q4 2024 | -$0.83 | +$0.51 |
XGN is still losing money, but far less than before: $0.76 per share over the past year, against $2.77 at its worst in late 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over XGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over XGN on profitability, with a higher operating margin.
XGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.4M | +6.8% |
| Q2 2026 | $19.9M | +16% |
| Q1 2026 | $17.3M | +12% |
| Q4 2025 | $16.6M | +22% |
| Q3 2025 | $17.2M | +38% |
| Q2 2025 | $17.2M | +14% |
| Q1 2025 | $15.5M | +7.5% |
| Q4 2024 | $13.7M | -0.8% |
XGN's revenue has grown year over year for seven quarters in a row: $18M last quarter, up 6.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -24% | -5.9 points |
| Q2 2026 | -8.6% | +6.6 points |
| Q1 2026 | -20% | +2 points |
| Q4 2025 | -30% | -5.1 points |
| Q3 2025 | -18% | +19 points |
| Q2 2025 | -15% | +1.9 points |
| Q1 2025 | -22% | -0.9 points |
| Q4 2024 | -25% | +13 points |
XGN's operating margin was −24% last quarter, down 5.9 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over XGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
XGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.8M | -204% |
| Q2 2026 | $3.4M | +$6.5M |
| Q1 2026 | -$10.6M | +$139K |
| Q4 2025 | -$3.1M | -1509% |
| Q3 2025 | $2.7M | +$5M |
| Q2 2025 | -$3.1M | -$532K |
| Q1 2025 | -$10.8M | -$1.7M |
| Q4 2024 | $217K | -97% |
XGN has burned cash in almost every quarter: −$13M over the past year, against −$11M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over XGN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
XGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.8% | +685K shares |
| 1 year | +8.3% | +1.9M shares |
| 3 years | +40% | +7.2M shares |
| 5 years | +47% | +7.9M shares |
| Available history | +97% | +12.3M shares |
XGN has 25M diluted shares, up 8.3% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
XGN Net Leverage
XGN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
XGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.3 | Neutral |
| Stochastic | 38.4 | Neutral |
XGN's weekly RSI is 40 (neutral) and its Stochastic is 38 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
XGN PE vs Healthcare Sector
XGN has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over XGN on trend strength, trading above more of its moving averages.
XGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.39 | 40% below |
| 20 week MA | $6.68 | 34% below |
| 50 week MA | $5.21 | 15% below |
| 100 week MA | $6.05 | 27% below |
| 200 week MA | $4.23 | 4.3% above |
XGN has fallen below most of its moving averages, though it's still 4.3% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over XGN on returns for 2026, with the stronger performance.
XGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.7 | $12.3 | -52% |
| 2021 | $12.3 | $11.0 | -10% |
| 2022 | $11.0 | $2.45 | -78% |
| 2023 | $2.45 | $1.99 | -19% |
| 2024 | $1.99 | $4.71 | +137% |
| 2025 | $4.71 | $6.13 | +30% |
| 2026 YTD | $6.13 | $4.41 | -28% |
XGN's yearly returns have swung widely, from +137% in 2024 to −78% in 2022. It's down 28% so far in 2026.